A Phase 3 interventional study of pregabalin and pregabalin in Partial Seizures and Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 82 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pregabalin in Seizures — none open to participants now, none under way, none of them phase 3. Pregabalin · Seizures.
Among the 10 studies testing pregabalin in Seizures, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 9th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →None of the 10 studies testing pregabalin in Seizures is open now. The open studies under Seizures, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2011.
This study's enrollment of 325 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 276 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
12 studies in Seizures by Viatris Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Seizures by Viatris Inc., this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 9 in phase 3, and was the 8th registered.
Viatris Inc.’s Seizures studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing pregabalin in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 12 in Seizures:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin
Drug: pregabalin
Drug: placebo
Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
matched to the active drug
Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
Time frame: Week 0 to Week 14
Percentage of Participants With a ≥50% Reduction in the 28-day Partial Seizure Rate From Baseline During the Double-blind Treatment Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Participants who had a ≥50% reduction in the 28-day partial seizure rate from baseline were defined as a responder, otherwise they were default as a non-responder.
Time frame: Week 0 to Week 14
Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
Time frame: Week 0 to Week 14
Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.
Time frame: Week 0 to Week 14
Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
Time frame: Week 2 to Week 14
Percentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.
Time frame: Week 0 to Week 14
Loge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
Time frame: Week 2 to Week 14
Change From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 14
Change From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 14
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Snoring Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Sleep Adequacy Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Sleep Somnolence Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 14
Percent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale
Optimal sleep was considered between 7 to 8 hours of average sleep per night inclusive, while average sleep less than or greater than the 7 to 8 hour of average sleep per night was non-optimal.
Time frame: Week 14
Benefit, Satisfaction, and Willingness to Continue Measure (BSW): Benefit From Treatment Question
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
Time frame: Week 14
BSW: Satisfaction From Treatment Question
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
Time frame: Week 14
BSW: Willingness to Continue Question
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
Time frame: Week 14
Percentage of Participants With New or Intensified Physical Examination Findings During the Double-blind Treatment Phase
Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal (abdominal rigidity and tenderness), an extremities (e.g. edema). Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.
Time frame: Day 1 to Week 15
Percentage of Participants With New or Intensified Neurological Examination Findings During the Double-blind Treatment Phase
Neurological examinations included level of consciousness, mental status, cranial nerve assessment, muscle strength, reflexes, pin prick and vibratory sensation (the latter using a 128-Hz tuning fork), coordination and gait.
Time frame: Day 1 to Week 15
Percentage of Participants With Self-injurious or Suicidal Ideation or Behavior on Columbia Classification Algorithm of Suicide Assessment (C-CASA)
C-CASA is described as a standardized suicidal rating system. The C-CASA has eight categories (4 suicidal events: completed suicide, suicide attempt, preparatory act toward imminent suicidal behavior (PAISB), and suicidal ideation; 2 nonsuicidal events: self-injurious behavior, no suicidal intent (SIB-NSI) and other no deliberate self-harm, and 2 indeterminate or potentially suicidal events: self-injurious behavior, suicidal intent unknown and not enough information) that distinguish suicidal events from nonsuicidal events and indeterminate or potentially suicidal events.
Time frame: Week -8 (Screening), Week 0 (Baseline), and Week 14 (double-blind treatment phase)
Percentage of Participants With a Relevant Increase in Sitting Blood Pressure (BP) From Baseline During the Double-blind Treatment Phase
Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest (ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal(abdominal rigidity and tenderness), an extremities (e.g. edema).
Time frame: Day 1 to Week 15
Percentage of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 450 ms
The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) were calculated.
Time frame: Week 15
Percentage of Participants With Relevant ECG Interval-increases From Baseline During the Double-blind Treatment Phase
The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. 25/50% represents ≥25% or ≥50% increase over baseline respectively, based on cut points. Cut points are 100 ms for QRS and 200 ms for PR.
Time frame: Week 15
Percentage of Participants With Laboratory Test Abnormalities During the Study
Laboratory samples in hematology, chemistry, and urinalysis were analyzed by a cental laboratory. Any laboratory value that was identified as clinically significant was reported as an AE. LLN: Lower limit of normal, ULN: Uper limit of normal, RBC: Red Blood Cell, WBC: White Blood Cell, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood Urea Nitrogen
Time frame: Day 1 to Week 15
This was a multicenter, multinational study and included four standard phases: an 8-week baseline observation phase, a 2-week dose escalation phase, a 12-week fixed-dose maintenance phase, and a 1-week taper phase.
| Milestone | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Started | 100 | 113 | 110 |
| Completed | 91 | 98 | 98 |
| Not completed | 9 | 15 | 12 |
| Withdrew: Does not meet entrance criteria | 0 | 2 | 0 |
| Withdrew: Insufficient clinical response | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: No longer willing to participate | 3 | 3 | 2 |
| Withdrew: Reason not provided | 2 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Adverse event (ae) related to study drug | 3 | 8 | 3 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
| ln (seizures per 28 days) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Baseline | 2.24 ± 0.757 | 2.33 ± 0.873 | 2.32 ± 0.910 |
| Week 14 | 1.84 ± 1.003 | 1.80 ± 1.030 | 1.93 ± 1.132 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Participants who had a ≥50% reduction in the 28-day partial seizure rate from baseline were defined as a responder, otherwise they were default as a non-responder.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Responder | 37.8 | 45.9 | 35.8 |
| Non-responder | 62.2 | 54.1 | 64.2 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
| ln (seizures per 28 days) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Percentage Change From Baseline in 28-day Partial Seizure Rate During the Double-blind Treatment Phase | -15.00 ± 11.668 | -31.54 ± 10.772 | -5.70 ± 10.918 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.
| seizures per 28 days | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Frequency of Secondary Generalized Tonic-clonic Seizures (SGTC) During the Double-blind Treatment Phase | 3.99 ± 8.667 | 4.43 ± 14.736 | 7.51 ± 24.979 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
| ln (seizures per 28 days) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Log Transformed 28-day SGTC Rate for All SGTCs During the Double-blind Maintenance Phase | 0.46 ± 0.049 | 0.48 ± 0.045 | 0.48 ± 0.046 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With ≥50% Reduction in 28-day SGTC Seizure Rate From Baseline During the Double-blind Treatment Phase | 1.0 | 1.9 | 1.9 |
Seizures were recorded and documented in a daily Seizure Diary by the participants, family member, caregiver, or legal guardian. Simple partial seizures without a visible motor component (ie, lacking visible movements during the seizure) were not counted toward eligibility, or in the primary or secondary efficacy analyses. Natural logarithm of the 28-day seizure rate was reported in this outcome measure.
| ln(28-day seizure rate) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Loge 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Maintenance Phase | 1.91 ± 0.070 | 1.77 ± 0.064 | 1.88 ± 0.065 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at Week 14 | -0.8 ± 3.34 | -0.4 ± 3.19 | -0.5 ± 3.13 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at Week 14 | -0.5 ± 3.16 | -0.8 ± 3.49 | -0.1 ± 3.17 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Score at Week 14 | -3.9 ± 19.89 | -1.5 ± 17.93 | -1.9 ± 14.10 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Snoring Score at Week 14 | -3.5 ± 25.44 | 5.4 ± 26.00 | -0.6 ± 22.71 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Awaken Short of Breath or With Headache Score at Week 14 | 0.2 ± 20.75 | 1.0 ± 24.48 | -0.8 ± 18.96 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| hours | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Quantity of Sleep (Hours) at Week 14 | 0.2 ± 1.31 | -0.1 ± 1.18 | -0.1 ± 1.25 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Sleep Adequacy Score at Week 14 | 2.3 ± 31.14 | -1.7 ± 31.44 | -1.5 ± 24.55 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Sleep Somnolence Score at Week 14 | -0.5 ± 17.29 | 5.2 ± 19.42 | 5.0 ± 18.72 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in MOS-SS - Sleep Problems Index I Score at Week 14 | -2.2 ± 16.91 | 0.4 ± 16.43 | 0.3 ± 12.62 |
Participant-rated 12-item questionnaire to assess key constructs of sleep over the past week. 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes: 1, no: 0). 6 and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
| units on a scale | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Problems Index II Score at Week 14 | -2.4 ± 15.62 | 0.7 ± 14.53 | 0.7 ± 11.30 |
Optimal sleep was considered between 7 to 8 hours of average sleep per night inclusive, while average sleep less than or greater than the 7 to 8 hour of average sleep per night was non-optimal.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Percent of Participants Reporting Optimal Sleep on the MOS-SS - Optimal Sleep Subscale | 67.7 | 60.2 | 60.2 |
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| No | 12.0 | 17.9 | 22.0 |
| Little benefit | 31.0 | 23.2 | 33.0 |
| Much benefit | 54.0 | 56.3 | 42.2 |
| Not done | 2.0 | 1.8 | 1.8 |
| Missing | 1.0 | 0.9 | 0.9 |
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| No | 13.0 | 17.9 | 23.9 |
| Yes | 84.0 | 80.4 | 73.4 |
| Missing | 3.0 | 1.8 | 2.8 |
The BSW consisted of 3 single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was read aloud to the participant by the investigator or designated center personnel and then was given to the participant to complete independently.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| No | 18.0 | 22.3 | 26.6 |
| Yes | 79.0 | 75.9 | 70.6 |
| Missing | 3.0 | 1.8 | 2.8 |
Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal (abdominal rigidity and tenderness), an extremities (e.g. edema). Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| General | 1.0 | 2.7 | 0.0 |
| Skin | 2.0 | 6.2 | 4.5 |
| Head | 1.0 | 1.8 | 0.0 |
| Ears | 3.0 | 1.8 | 0.9 |
| Eyes | 1.0 | 2.7 | 3.6 |
| Nose | 0.0 | 0.0 | 1.8 |
| Throat | 0.0 | 0.0 | 1.8 |
| Lungs | 0.0 | 0.0 | 0.0 |
| Heart | 1.0 | 0.0 | 0.0 |
| Abdomen | 0.0 | 0.0 | 0.0 |
| Extremities | 2.0 | 2.7 | 1.8 |
| Other | 14.0 | 7.1 | 10.9 |
Neurological examinations included level of consciousness, mental status, cranial nerve assessment, muscle strength, reflexes, pin prick and vibratory sensation (the latter using a 128-Hz tuning fork), coordination and gait.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| None | 79.0 | 78.8 | 68.2 |
| Any | 21.0 | 21.2 | 31.8 |
| Coordination | 1.0 | 1.8 | 1.8 |
| Cranial nerve function | 0.0 | 0.9 | 0.0 |
| Cranial nerve II | 0.0 | 0.0 | 0.0 |
| Cranial nerve III | 0.0 | 0.0 | 1.8 |
| Cranial nerve V | 0.0 | 0.0 | 0.0 |
| Cranial nerve VII | 1.0 | 0.0 | 0.9 |
| Cranial nerve VIII | 0.0 | 0.9 | 0.0 |
| Cranial nerve XI | 0.0 | 0.0 | 0.0 |
| Deep tendon reflexes | 3.0 | 1.8 | 2.7 |
| Gait and station | 0.0 | 0.0 | 0.9 |
| Level of consciousness | 0.0 | 0.0 | 0.9 |
| Mental state | 1.0 | 1.8 | 1.8 |
| Motor function | 1.0 | 2.7 | 3.6 |
| Muscle strength | 2.0 | 0.0 | 1.9 |
| Pain sensation | 0.0 | 0.0 | 1.9 |
| Reflexes | 1.0 | 0.9 | 1.9 |
| Vibration | 11.1 | 10.8 | 12.0 |
C-CASA is described as a standardized suicidal rating system. The C-CASA has eight categories (4 suicidal events: completed suicide, suicide attempt, preparatory act toward imminent suicidal behavior (PAISB), and suicidal ideation; 2 nonsuicidal events: self-injurious behavior, no suicidal intent (SIB-NSI) and other no deliberate self-harm, and 2 indeterminate or potentially suicidal events: self-injurious behavior, suicidal intent unknown and not enough information) that distinguish suicidal events from nonsuicidal events and indeterminate or potentially suicidal events.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Suicide attempt (Lifetime prior to Screening) | 2.0 | 1.8 | 5.5 |
| PAISB (Lifetime prior to Screening) | 1.0 | 1.8 | 4.5 |
| Suicidal ideation (Lifetime prior to Screening) | 11.0 | 10.6 | 14.5 |
| SIB-NSI (Lifetime prior to Screening) | 1.0 | 0.9 | 0.9 |
| Suicide attempts at Week 0 | 1.0 | 0.9 | 0.0 |
| PAISB at Week 0 | 0.0 | 0.9 | 0.0 |
| Suicidal ideation at Week 0 | 8.0 | 7.1 | 2.7 |
| SIB-NSI at Week 0 | 1.0 | 0.0 | 0.0 |
| Suicidal ideation at Week 14 | 4.0 | 2.7 | 1.8 |
Physical examinations included general appearance (including hight at baseline), vital sign (sitting heart rate and sitting blood pressure), weight, skin (examination for the presence of rash), HEENT (examinatin of head, eyes, ears, nose and throat), chest (ausculation of lung fields), cardiovascular (ausculatin of heart sounds (S1 and S2) and for the presence of murmurs, gallops, or rubs), gastrointestinal(abdominal rigidity and tenderness), an extremities (e.g. edema).
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Maximum increase in systolic BP ≥30 mmHg | 1.0 | 1.8 | 0.9 |
| Maximum increase in diastolic BP ≥20 mmHg | 5.1 | 5.5 | 2.8 |
The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB) were calculated.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Maximum QTcB 450 - <480 | 8.0 | 5.3 | 10.0 |
| Maximum QTcB 480 - <500 | 1.0 | 0.0 | 0.9 |
| Maximum QTcB ≥500 | 0.0 | 1.8 | 0.0 |
| Maximum QTcF 450 - <480 | 3.0 | 2.7 | 3.6 |
| Maximum QTcF 480 - <500 | 1.0 | 0.0 | 0.0 |
| Maximum QTcF ≥500 | 0.0 | 0.0 | 0.0 |
The original ECG was reviewed by the investigator and kept on site as part of source documentation. A central ECG reader was also used for this study. 25/50% represents ≥25% or ≥50% increase over baseline respectively, based on cut points. Cut points are 100 ms for QRS and 200 ms for PR.
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Max PR interval rise:%change≥25/50% | 1.1 | 1.0 | 2.1 |
| Max QRS complex rise:%change≥25/50% | 1.1 | 1.9 | 1.0 |
| Max. QTcB interval rise: 30≤x<60 | 5.4 | 1.9 | 3.1 |
| Max. QTcB interval rise: ≥60 | 0.0 | 1.9 | 0.0 |
| Max. QTcF interval rise: 30≤x<60 | 3.2 | 1.9 | 2.1 |
| Max. QTcF interval rise: ≥60 | 0.0 | 0.0 | 0.0 |
Laboratory samples in hematology, chemistry, and urinalysis were analyzed by a cental laboratory. Any laboratory value that was identified as clinically significant was reported as an AE. LLN: Lower limit of normal, ULN: Uper limit of normal, RBC: Red Blood Cell, WBC: White Blood Cell, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood Urea Nitrogen
| percentage of participants | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| Hemoglobin (HGB) <0.8xLLN , | 1.0 | 0.9 | 0.9 |
| Hematocrit (HCT) <0.8xLLN | 0.0 | 0.9 | 0.0 |
| RBC Count <0.8xLLN | 0.0 | 0.0 | 0.0 |
| Platelets <0.5xLLN | 0.0 | 0.0 | 0.0 |
| Platelets >1.75xULN | 0.0 | 0.0 | 0.0 |
| WBC Count <0.6xLLN | 0.0 | 0.9 | 0.0 |
| White Blood Cell Count >1.5xULN | 0.0 | 0.0 | 0.0 |
| Lymphocytes (absolute) <0.8xLLN | 4.2 | 0.9 | 1.9 |
| Lymphocytes (absolute) >1.2xULN | 2.1 | 1.8 | 3.8 |
| Lymphocytes (%) <0.8xLLN | 0.0 | 0.0 | 1.9 |
| Lymphocytes (%) >1.2xULN | 1.0 | 0.0 | 0.9 |
| Neutrophils (absolute) <0.8xLLN | 3.1 | 1.8 | 1.9 |
| Neutrophils (absolute) >1.2xULN | 0.0 | 0.0 | 1.9 |
| Neutrophils (%) <0.8xLLN | 1.0 | 0.0 | 0.0 |
| Neutrophils (%) >1.2xULN | 0.0 | 0.0 | 0.0 |
| Basophils (absolute) >1.2xULN | 0.0 | 0.0 | 0.0 |
| Basophils (%) >1.2xULN | 0.0 | 0.0 | 0.0 |
| Eosinophils (absolute) >1.2xULN | 3.1 | 3.7 | 1.9 |
| Eosinophils (%) >1.2xULN | 6.3 | 4.6 | 3.8 |
| Monocytes (absolute) >1.2xULN | 0.0 | 1.8 | 0.0 |
| Monocytes (%) >1.2xULN | 1.0 | 0.0 | 0.0 |
| Total Bilirubin >1.5xULN | 0.0 | 0.0 | 0.0 |
| AST >3.0xULN | 0.0 | 0.0 | 0.0 |
| ALT >3.0xULN | 0.0 | 0.0 | 0.0 |
| Alkaline Phosphatase >3.0xULN | 0.0 | 0.0 | 0.0 |
| Total Protein <0.8xLLN | 0.0 | 0.0 | 0.0 |
| Total Protein >1.2xULN | 0.0 | 0.0 | 0.0 |
| Albumin <0.8xLLN | 0.0 | 0.0 | 0.0 |
| Albumin >1.2xULN | 0.0 | 0.0 | 0.0 |
| BUN >1.3xULN | 0.0 | 0.0 | 0.0 |
| Creatinine >1.3xULN | 0.0 | 0.0 | 0.0 |
| Uric Acid >1.2xULN | 1.0 | 0.9 | 0.0 |
| Sodium <0.95xLLN | 1.0 | 0.0 | 0.0 |
| Sodium >1.05xULN | 0.0 | 0.0 | 0.0 |
| Potassium <0.9xLLN | 2.0 | 0.0 | 0.0 |
| Potassium >1.1xULN | 1.0 | 0.0 | 0.0 |
| Chloride <0.9xLLN | 0.0 | 0.0 | 0.0 |
| Chloride >1.1xULN | 0.0 | 0.0 | 0.0 |
| Calcium <0.9xLLN | 0.0 | 0.0 | 0.0 |
| Calcium >1.1xULN | 0.0 | 0.0 | 0.0 |
| Glucose <0.6xLLN | 0.0 | 0.0 | 0.0 |
| Glucose >1.5xULN | 0.0 | 0.9 | 0.0 |
| Urine Specific Gravity <1.003 | 0.0 | 1.9 | 1.0 |
| Urine Specific Gravity >1.030 | 1.1 | 1.9 | 4.8 |
| Urine pH <4.5 | 0.0 | 0.0 | 0.0 |
| Urine pH >8 | 1.1 | 1.9 | 1.9 |
| Urine Glucose (qualitative) ≥1 | 0.0 | 0.9 | 0.0 |
| Urine Ketones (qualitative) ≥1 | 2.1 | 1.9 | 1.9 |
| Urine Protein (qualitative) ≥1 | 3.2 | 2.8 | 1.0 |
| Urine Blood/Hgb (qualitative) ≥1 | 8.5 | 9.4 | 9.5 |
| Urine Nitrite ≥1 | 11.7 | 5.7 | 13.3 |
| Urine RBC ≥20 | 13.3 | 0.0 | 9.5 |
| Urine WBC ≥20 | 4.8 | 3.7 | 29.6 |
Collected over From the time the participant provided informed consent, which was obtained prior to the participant's participation in the study, through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 165 mg | — | 5/100 (5%) | 14/100 (14%) |
| Pregabalin 330 mg | — | 5/113 (4.4%) | 21/113 (18.6%) |
| Placebo | — | 2/110 (1.8%) | 3/110 (2.7%) |
| Event | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| BronchitisInfections and infestations | 1/100 | 0/113 | 0/110 |
| PneumoniaInfections and infestations | 1/100 | 0/113 | 0/110 |
| Viral infectionInfections and infestations | 1/100 | 0/113 | 0/110 |
| Complex partial seizuresNervous system disorders | 1/100 | 0/113 | 0/110 |
| ConvulsionNervous system disorders | 1/100 | 1/113 | 1/110 |
| EpilepsyNervous system disorders | 1/100 | 0/113 | 0/110 |
| Grand mal convulsionNervous system disorders | 1/100 | 0/113 | 0/110 |
| WoundInjury, poisoning and procedural complications | 0/100 | 0/113 | 1/110 |
| Subcutaneous abscessInfections and infestations | 0/100 | 1/113 | 0/110 |
| AtaxiaNervous system disorders | 0/100 | 1/113 | 0/110 |
| Event | Pregabalin 165 mg | Pregabalin 330 mg | Placebo |
|---|---|---|---|
| DizzinessNervous system disorders | 11/100 | 11/113 | 2/110 |
| Weight increasedInvestigations | 1/100 | 7/113 | 0/110 |
| FatigueGeneral disorders | 3/100 | 6/113 | 1/110 |
The safety analysis set included all randomized participants who took at least one dose of the study medication.
| Age, Continuous(years) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 37.88 ± 13.10 | 39.58 ± 13.15 | 38.72 ± 13.25 | 38.76 ± 13.14 |
| Sex: Female, Male(Participants) | Pregabalin 165 mg | Pregabalin 330 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 53 | 55 | 61 | 169 |
| Male | 47 | 58 | 49 | 154 |
Ran from Feb 2011 to primary completion in Jul 2012, 17 months.
Results were first posted in Jun 2018, 5 years 10 months after primary completion. A results delay was requested in Sep 2013.
Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 17 months is below that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →